Principal Financial Group’s Arcus Biosciences RCUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.94M Buy
413,778
+6,265
+2% +$135K ﹤0.01% 1385
2025
Q4
$9.71M Buy
407,513
+72,989
+22% +$1.49M 0.01% 1334
2025
Q3
$4.55M Sell
334,524
-1,701
-0.5% -$17.7K ﹤0.01% 1624
2025
Q2
$2.74M Buy
336,225
+1,244
+0.4% +$10.6K ﹤0.01% 1747
2025
Q1
$2.63M Buy
334,981
+71,464
+27% +$829K ﹤0.01% 1724
2024
Q4
$3.92M Buy
263,517
+7,906
+3% +$129K ﹤0.01% 1663
2024
Q3
$3.91M Sell
255,611
-18,777
-7% -$296K ﹤0.01% 1636
2024
Q2
$4.18M Sell
274,388
-15,577
-5% -$251K ﹤0.01% 1595
2024
Q1
$5.47M Sell
289,965
-42,849
-13% -$741K ﹤0.01% 1536
2023
Q4
$6.36M Buy
332,814
+3,372
+1% +$53.9K ﹤0.01% 1478
2023
Q3
$5.91M Buy
329,442
+1,312
+0.4% +$26.4K ﹤0.01% 1465
2023
Q2
$6.66M Buy
328,130
+3,390
+1% +$64.6K ﹤0.01% 1426
2023
Q1
$5.92M Sell
324,740
-4,267
-1% -$81.6K ﹤0.01% 1480
2022
Q4
$6.8M Sell
329,007
-12,199
-4% -$336K 0.01% 1424
2022
Q3
$8.93M Buy
341,206
+9,429
+3% +$249K 0.01% 1248
2022
Q2
$8.41M Buy
331,777
+323,465
+3,892% +$7.92M 0.01% 1347
2022
Q1
$262K Sell
8,312
-268
-3% -$8.98K ﹤0.01% 2272
2021
Q4
$347K Sell
8,580
-5,499
-39% -$213K ﹤0.01% 2211
2021
Q3
$491K Sell
14,079
-2,283
-14% -$71.1K ﹤0.01% 2176
2021
Q2
$449K Sell
16,362
-7,052
-30% -$201K ﹤0.01% 2240
2021
Q1
$657K Sell
23,414
-666
-3% -$23.2K ﹤0.01% 2085
2020
Q4
$625K Buy
+24,080
New +$583K ﹤0.01% 2055

Other funds holding RCUS

Principal Financial Group's RCUS Position: Q1 2026 in Review

Principal Financial Group increased its Arcus Biosciences (RCUS) stake by 1.5% in Q1 2026, buying an estimated $135K and bringing the position to 413,778 shares worth $8.94M. The position accounts for ﹤0.01% of the portfolio, ranked #1385.

Principal Financial Group first reported a position in RCUS in Q4 2020 and has held it in 22 quarters since. The position peaked at $9.71M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Principal Financial Group held 413,778 shares of Arcus Biosciences worth $8.94M as of Q1 2026.
  • Principal Financial Group bought 6,265 Arcus Biosciences shares in Q1 2026, an estimated $135K.
  • Arcus Biosciences made up ﹤0.01% of Principal Financial Group's portfolio in Q1 2026, its #1385 holding.
  • Principal Financial Group first reported a position in Arcus Biosciences in Q4 2020 and has held it in 22 quarters since.
  • Principal Financial Group's Arcus Biosciences position peaked at $9.71M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Principal Financial Group's 13F filing for Q1 2026, filed 4 May 2026.